Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma
The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and me...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2214478 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238238585782272 |
|---|---|
| author | Benjamin Koh Darren Jun Hao Tan Wen Hui Lim Jeffrey S L Wong Cheng Han Ng Kai En Chan Meng Wang Wei Peng Yong Yock Young Dan Louis Z Wang Nigel Tan Mark Muthiah Alfred Kow Nicholas L. Syn Daniel Q. Huang Thomas Yau |
| author_facet | Benjamin Koh Darren Jun Hao Tan Wen Hui Lim Jeffrey S L Wong Cheng Han Ng Kai En Chan Meng Wang Wei Peng Yong Yock Young Dan Louis Z Wang Nigel Tan Mark Muthiah Alfred Kow Nicholas L. Syn Daniel Q. Huang Thomas Yau |
| author_sort | Benjamin Koh |
| collection | DOAJ |
| description | The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and mechanistic biomarkers and novel treatment strategies are urgently needed for patients who present with or acquire resistance to first-line ICI-based therapies. The recent approval of the STRIDE regimen has also engendered new questions, such as patient selection factors (e.g. portal hypertension and history of variceal bleed) and biomarkers, and the optimal combination and sequencing of ICI-based regimens. Triumphs in the setting of advanced HCC have also galvanized considerable interest in the broader application of ICIs to early- and intermediate-stage diseases, including clinical combination of ICIs with locoregional therapies. Among these clinical contexts, the role of ICIs in liver transplantation – which is a potentially curative strategy unique to HCC management – as a bridge to liver transplant in potential candidates or in the setting of post-transplant recurrence, warrants investigation in view of the notable theoretical risk of allograft rejection. In this review, we summarize and chart the landscape of seminal immuno-oncology trials in HCC and envision future clinical developments. |
| format | Article |
| id | doaj-art-98077533239642c291b0017f7ac49635 |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-98077533239642c291b0017f7ac496352025-08-20T02:01:30ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2214478Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinomaBenjamin Koh0Darren Jun Hao Tan1Wen Hui Lim2Jeffrey S L Wong3Cheng Han Ng4Kai En Chan5Meng Wang6Wei Peng Yong7Yock Young Dan8Louis Z Wang9Nigel Tan10Mark Muthiah11Alfred Kow12Nicholas L. Syn13Daniel Q. Huang14Thomas Yau15Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeDepartment of Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region, ChinaYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeDivision of Advanced Internal Medicine, Department of Medicine, National University Hospital, Singapore, SingaporeDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeSingHealth Internal Medicine Residency Programme, Singapore General Hospital, Singapore, SingaporeNational University Centre for Organ Transplantation, National University Health System, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeYong Loo Lin School of Medicine, National University of Singapore, Singapore, SingaporeDepartment of Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Special Administrative Region, ChinaThe use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and mechanistic biomarkers and novel treatment strategies are urgently needed for patients who present with or acquire resistance to first-line ICI-based therapies. The recent approval of the STRIDE regimen has also engendered new questions, such as patient selection factors (e.g. portal hypertension and history of variceal bleed) and biomarkers, and the optimal combination and sequencing of ICI-based regimens. Triumphs in the setting of advanced HCC have also galvanized considerable interest in the broader application of ICIs to early- and intermediate-stage diseases, including clinical combination of ICIs with locoregional therapies. Among these clinical contexts, the role of ICIs in liver transplantation – which is a potentially curative strategy unique to HCC management – as a bridge to liver transplant in potential candidates or in the setting of post-transplant recurrence, warrants investigation in view of the notable theoretical risk of allograft rejection. In this review, we summarize and chart the landscape of seminal immuno-oncology trials in HCC and envision future clinical developments.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2214478Hepatocellular carcinomaimmune checkpoint blockadeNeoadjuvant immunotherapyprecision immunotherapytransplant oncologytumor microenvironment |
| spellingShingle | Benjamin Koh Darren Jun Hao Tan Wen Hui Lim Jeffrey S L Wong Cheng Han Ng Kai En Chan Meng Wang Wei Peng Yong Yock Young Dan Louis Z Wang Nigel Tan Mark Muthiah Alfred Kow Nicholas L. Syn Daniel Q. Huang Thomas Yau Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma OncoImmunology Hepatocellular carcinoma immune checkpoint blockade Neoadjuvant immunotherapy precision immunotherapy transplant oncology tumor microenvironment |
| title | Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma |
| title_full | Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma |
| title_fullStr | Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma |
| title_full_unstemmed | Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma |
| title_short | Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma |
| title_sort | trial watch immunotherapeutic strategies on the horizon for hepatocellular carcinoma |
| topic | Hepatocellular carcinoma immune checkpoint blockade Neoadjuvant immunotherapy precision immunotherapy transplant oncology tumor microenvironment |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2214478 |
| work_keys_str_mv | AT benjaminkoh trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT darrenjunhaotan trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT wenhuilim trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT jeffreyslwong trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT chenghanng trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT kaienchan trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT mengwang trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT weipengyong trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT yockyoungdan trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT louiszwang trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT nigeltan trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT markmuthiah trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT alfredkow trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT nicholaslsyn trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT danielqhuang trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma AT thomasyau trialwatchimmunotherapeuticstrategiesonthehorizonforhepatocellularcarcinoma |